Kaya G Capa, Ertay T, Tuna B, Bekis R, Tasci C, Sayit E, Yilmaz O, Kargi A, Durak H
Department of Nuclear Medicine, Dokuz Eylül University, School of Medicine, Izmir, Turkey.
Lung. 2006 Mar-Apr;184(2):57-61. doi: 10.1007/s00408-005-2562-3.
Amiodarone (AD)-induced pulmonary toxicity is one of the major complications of long-term AD therapy. Technetium-99m-labeled D: ,L: -hexamethylpropylene amine oxime (Tc-99m HMPAO) scintigraphy has been used to assess lung injury. We designed this study to clarify lung uptake changes of Tc-99m HMPAO using low doses of AD (5 mg/kg/day) during long-term therapy in a rabbit model. Group 1 consisted of 7 rabbits fed with AD by gavage for 6 months. To investigate the effect of ketamine on Tc-99m HMPAO uptake, 5 rabbits were included in Group 2 as a control group. Tc-99m HMPAO scintigraphy was performed in both Group 1 and Group 2 at baseline and after 2, 4, 6, 8, and 12 weeks of AD intake. After 16, 20, and 24 weeks of drug intake, Tc-99m HMPAO scintigraphy was repeated only in group 1. One-min anterior images were acquired 30 min after the injection of 37 MBq of Tc-99m HMPAO. For semiquantitative evaluation, the mean count values were obtained and lung/background and liver/background ratios were calculated. Histopathologic evaluation was performed. No increase in lung and liver uptake of Tc-99m HMPAO was found 2, 4, 6, 8, and 12 weeks after drug intake. There was no significant increase in L/B and H/B ratios of Tc-99m HMPAO in Group 1 compared with Group 2. Both scintigraphic studies and histopathologic examinations showed nonspecific changes. Longitudinal studies investigating Tc-99m HMPAO lung uptake may be planned in patients carrying risk factors for AD-induced lung toxicity.
胺碘酮（AD）诱发的肺毒性是长期AD治疗的主要并发症之一。锝-99m标记的D，L-六甲基丙烯胺肟（Tc-99m HMPAO）闪烁扫描已用于评估肺损伤。我们设计本研究以阐明在兔模型中长期治疗期间使用低剂量AD（5mg/kg/天）时Tc-99m HMPAO的肺摄取变化。第1组由7只通过灌胃给予AD 6个月的兔子组成。为研究氯胺酮对Tc-99m HMPAO摄取的影响，第2组纳入5只兔子作为对照组。第1组和第2组在基线时以及AD摄入2、4、6、8和12周后进行Tc-99m HMPAO闪烁扫描。在药物摄入16、20和24周后，仅在第1组重复进行Tc-99m HMPAO闪烁扫描。在注射37MBq的Tc-99m HMPAO后30分钟采集1分钟的前位图像。为进行半定量评估，获取平均计数值并计算肺/本底和肝/本底比值。进行了组织病理学评估。在药物摄入后2、4、6、8和12周，未发现Tc-99m HMPAO在肺和肝中的摄取增加。与第2组相比，第1组中Tc-99m HMPAO的L/B和H/B比值无显著增加。闪烁扫描研究和组织病理学检查均显示非特异性变化。对于有AD诱发肺毒性危险因素的患者，可计划进行研究Tc-99m HMPAO肺摄取的纵向研究。
